Entera Bio (ENTX) Director Steven Rubin Receives Equity Awards

What Happened Steven D. Rubin, a director of Entera Bio Ltd. (ENTX), was granted equity awards reported on Aug 7, 2026 (transaction code A). The filing shows: 19,117 ordinary shares awarded (issued in lieu of cash director fees) and two option grants covering 33,368 and 43,405 underlying shares (total options = 76,773). The Form 4 reports an acquisition price of $0.00 for these awards (grants, not purchases).

Key Details

• Transaction date and price: Aug 7, 2026; reported acquisition price $0.00 (award/grant).
• Award breakdown: 19,117 shares (awarded in lieu of Q1/Q2 2026 cash fees); options for 33,368 and 43,405 underlying shares.
• Vesting (per footnotes): one option grant vests over 3 years beginning Feb 1, 2026 (1/3 on Feb 1, 2027, then quarterly ratable over remaining two years); the other vests quarterly over a one‑year period that began Feb 1, 2026. Both include full acceleration upon a Change in Control.
• Approvals and registration: Board approved share award Aug 5, 2026; option grants approved May 7, 2026 and ratified by shareholders July 14, 2026; a Form S‑8 registering the shares was filed Aug 7, 2026.
• Shares owned after transaction: not disclosed in the provided excerpt — see the full Form 4 for total beneficial ownership.
• Timeliness: Reported and filed on Aug 7, 2026 (no late filing indicated).

Context These filings reflect compensation-related grants (awards and option grants), not open‑market purchases or sales. The options are grants to buy shares in the future (derivative instruments) and were not exercised in this filing. Compensation awards are common for directors and do not by themselves indicate insider buying or selling sentiment. Transaction code key: A = Award/Grant.